Thus, we decided to expand our studies to not only include silencing of ERK1 and/or ERK2, but to compare and contrast the biological responses and bypass mechanisms triggered by exposing A375 melanoma cells to PLX4032, as well as a MEK inhibitor (PD0325901). The gene discussed is MAPK1; the disease is melanoma.